Patients
Clinical Trials
At Celldex, we are pioneering new horizons in immunology to deliver life-changing therapies. We understand the importance of bringing these therapies to the broadest group of patients as quickly as possible.
By taking part in clinical trials, patients can make an important contribution to ongoing research and better understanding of a disease.
Clinical studies collect the information necessary to understand the safety and efficacy of the potential therapy allowing for regulatory review and potential approval.
To learn more about our ongoing clinical trials or to find out if a study is enrolling patients in your area, please visit www.clinicaltrials.gov or email clinicaltrials@celldex.com.
| Candidate | Indication | Phase | Status | Learn More |
Barzolvolimab |
Chronic Spontaneous Urticaria | Phase 3 | Actively enrolling | NCT06445023 / NCT06455202 Patient Recruitment |
Barzolvolimab |
Chronic Inducible Urticaria (Cold Contact Urticaria, Symptomatic Dermographism) | Phase 2 | Enrollment complete | NCT05405660 |
Barzolvolimab |
Eosinophilic Esophagitis | Phase 2 | Enrollment complete | NCT05774184 |
Barzolvolimab |
Prurigo Nodularis | Phase 2 | Actively enrolling | NCT06366750 Patient Recruitment |
Barzolvolimab |
Atopic Dermatitis | Phase 2 | Actively enrolling | NCT06727552 Patient Recruitment |
CDX-622 |
Healthy Participants | Phase 1 | Actively enrolling | NCT06650761 |
Compassionate Use at Celldex Therapeutics
At Celldex, we are pioneering new horizons in immunology to deliver life-changing therapies. Before our investigational medicines can be made broadly available, the U.S. Food and Drug Administration (FDA) and other worldwide health authorities require that they are studied in clinical trials to determine if they are safe and effective.
At Celldex, our focus is on enrolling patients in clinical trials to obtain the data required for review and approval by these regulatory authorities. People who take part in clinical trials play important roles in the development of new treatments.
In some instances, patients with serious or life-threatening diseases may not be eligible for any clinical trials and may not have other treatment options. In very specific circumstances, Celldex may provide access to our investigational products to patients with life-threatening diseases who have exhausted other treatment options and where there is a reasonable expectation of benefit over risk as defined in our Compassionate Use or Expanded Access Program.
In general, a treating physician, who has experience with the investigational product and is able to comply with the requirements that are stated in our Program, may apply for access to Celldex’s investigational products on behalf of their patient(s).
Additional Resources
ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies conducted around the world. The database includes robust search functionality to identify potential clinical trials.
The U.S. Food & Drug Administration’s website provides valuable information on Expanded Access/Compassionate Use.